Abstract Number: 1679 • 2014 ACR/ARHP Annual Meeting
A Double Blind Randomized Control Trial of Oral Tadalafil in Interstitial Lung Disease of Scleroderma
Background/Purpose We conducted a single center double-blind, randomized, placebo-controlled trial to determine the effects of oral Tadalafil on lung function and health-related symptoms in patients…Abstract Number: 1678 • 2014 ACR/ARHP Annual Meeting
Initial Therapy with an Endothelin Receptor Antagonist Is Associated with Worse Outcomes in Patients with Systemic Sclerosis and Pulmonary Arterial Hypertension: Observations from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Cohort
Background/Purpose: Pulmonary arterial hypertension (PAH) is a leading cause of mortality in systemic sclerosis (SSc). Although medications have improved their prognosis, optimal therapy remains undefined.…Abstract Number: 1677 • 2014 ACR/ARHP Annual Meeting
Association of Gastrointestinal Symptoms with Immunosuppressant Use in the Prospective Registry of Early Systemic Sclerosis Cohort
Background/Purpose: The Prospective Registry of Early Systemic Sclerosis (PRESS) is a multicenter incident cohort study of patients with early diffuse cutaneous systemic sclerosis (dcSSc; <…Abstract Number: 1658 • 2014 ACR/ARHP Annual Meeting
Renal Thrombotic Microangiopathy in Systemic Lupus Erythematosus: Novel Risk Factors and Clinical Outcomes
Background/Purpose: Thrombotic microangiopathy (TMA) is characterized by microvascular occlusion, systemic or intrarenal platelet aggregation and mechanical injury to erythrocytes. It is a pathological endpoint that…Abstract Number: 1656 • 2014 ACR/ARHP Annual Meeting
Rate of Histological Transformation to Higher Grade Nephritis in Class II Mesangial Proliferative Lupus Glomerulonephritis
Background/Purpose: Class II mesangial proliferative lupus nephritis has generally been considered a mild form of the condition, with a good response to glucocorticoid treatment. However,…Abstract Number: 1655 • 2014 ACR/ARHP Annual Meeting
Lupus Nephritis: Clinicopathological Correlation in 126 Biopsies
Background/Purpose: To analyze the correlation between clinical and laboratory data and type of histological injury in a cohort of patients with lupus nephritis (LN). Methods:…Abstract Number: 1654 • 2014 ACR/ARHP Annual Meeting
Thrombotic Microangiopathy and Poor Renal Outcome in Lupus Patients Is Not Associated with Antiphospholipid Syndrome and/or Other Lupus Conventional Features
Background/Purpose: To assess acute thrombotic microangiopathy (aTMA) and chronic vascular lesions (cTMA) in lupus nephropathy and to evaluate their association with extrarrenal lupus features, antiphospholipid…Abstract Number: 1653 • 2014 ACR/ARHP Annual Meeting
Serum Cystatin C As a Biomarker for Clinical Practice in Patients with Lupus Nephritis
Background/Purpose: Cystatin C has been developed as a novel biomarker of renal function in last decade and thought as more sensitive than serum creatinine (sCr).…Abstract Number: 1652 • 2014 ACR/ARHP Annual Meeting
Biomarkers of Lupus Nephritis and Ethnic Disparities in Systemic Lupus Erythematosus
Background/Purpose: Lupus nephritis eventually occurs in 50% of Caucasian SLE patients and 75% of African-Americans. African Americans have a more severe presentation of SLE and…Abstract Number: 1651 • 2014 ACR/ARHP Annual Meeting
Association of Glomerular Macrophage Phenotypes and Urine Soluble CD163 with Disease Activity in Human Lupus Nephritis
Background/Purpose: In addition to the effector roles of classically activated macrophages for tissue injury, recent studies have shown that alternatively activated (M2) macrophages are involved…Abstract Number: 1649 • 2014 ACR/ARHP Annual Meeting
High Specificity of Skin Immunoglobulin Deposits for diagnosing SLE in Patients with Lupus Nephritis
Background/Purpose: Deposit of different classes of immunoglobulins is the main feature of lupus nephritis;1 because of its high specificity, a patient is classified as having…Abstract Number: 1650 • 2014 ACR/ARHP Annual Meeting
Prevalence and Prognostic Implications of IgG4 in Membranous Lupus Nephritis
Background/Purpose: Patients with membranous lupus nephritis (MLN) have increased risk of thrombosis and different prognosis than other classes of lupus nephritis (LN). Previous studies demonstrated…Abstract Number: 1648 • 2014 ACR/ARHP Annual Meeting
Urinary T Cells and Macrophages Strongly Reflect the Disease Activity, Kidney Function, and the Histopathologic Classification in Patients with Lupus Nephritis
Background/Purpose: Lupus nephritis (LN) is one of the common manifestations of systemic lupus erythematosus (SLE), and the occurrence of LN is considered to be a…Abstract Number: 1647 • 2014 ACR/ARHP Annual Meeting
Relationship Between Apom/S1P Levels and Atherosclerosis in Women with Systemic Lupus Erythematosus
Background/Purpose: SLE patients are at risk for atherosclerotic cardiovascular disease (ASCVD). In some SLE patients, high density lipoprotein (HDL) has impaired vasoprotective effects, and this…Abstract Number: 1646 • 2014 ACR/ARHP Annual Meeting
Molecular, Cellular and Histopathologic Assessment of Baseline Characteristics of Sixteen Subjects with Discoid Lupus Erythematosus Prior to Treatment with AMG 811 (anti-IFNγ)
Background/Purpose Discoid Lupus Erythematosus (DLE), the most common chronic cutaneous form seen in LE, includes inflammation leading to scarring, telangiectasias, atrophy, and/or dyspigmentation. Elevated levels…
ACR Meeting Abstracts